20:37:49 EDT Fri 19 Apr 2024
Enter Symbol
or Name
USA
CA



Q:PRTC - PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
PRTC - Q0.113.65·42.030.226.15-0.12-0.50.241326.15  26.15  26.1534.00  17.0816:00:00Apr 1815 min RT 2¢

Recent Trades - Last 10 of 13
Time ETExPriceChangeVolume
16:00:00Q26.90-0.0351
15:26:10Q27.080.1451
15:19:43Q27.330.3951
15:18:56Q27.330.3951
13:55:46Q25.20-1.7351
13:31:43Q26.26-0.6751
13:30:43Q28.771.8351
12:40:06Q26.50-0.43515
11:30:54Q26.25-0.6851
11:16:47Q25.98-0.9551

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-18 02:00U:PRTCNews ReleasePureTech Health: Notice of Results
2024-04-16 07:00U:PRTCNews ReleasePureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis
2024-04-11 07:00U:PRTCNews ReleasePureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers
2024-04-09 02:00U:PRTCNews ReleasePureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions
2024-03-19 03:00U:PRTCNews ReleasePureTech Proposes $100 Million Capital Return
2024-03-18 09:52U:PRTCNews ReleaseBristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
2024-03-13 07:00U:PRTCNews ReleasePureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid Leukemia
2024-02-27 07:00U:PRTCNews ReleasePureTech to Present at Two Upcoming Investor Conferences
2024-02-27 02:00U:PRTCNews ReleasePureTech Founded Entity Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx (TM) for Pediatric ADHD Patients in Japan
2024-01-03 07:00U:PRTCNews ReleasePureTech to Present at 42nd Annual J.P. Morgan Healthcare Conference
2023-12-22 09:13U:PRTCNews ReleasePureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
2023-12-20 02:00U:PRTCNews ReleasePureTech Year End Update and Outlook for 2024
2023-12-07 06:00U:PRTCNews ReleasePureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023
2023-11-29 10:17U:PRTCNews ReleasePureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
2023-11-17 02:00U:PRTCNews ReleasePureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
2023-11-14 02:00U:PRTCNews ReleasePureTech's LYT-300 (Oral Allopregnanolone) Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Healthy Volunteers
2023-10-17 02:00U:PRTCNews ReleasePureTech to Present at Two Upcoming Investor Conferences
2023-10-11 07:00U:PRTCNews ReleasePureTech Presents Data from LYT-100 (Deupirfenidone) Trial in Healthy Older Adults at CHEST Annual Meeting
2023-10-04 07:05U:PRTCNews ReleasePureTech Founded Entity Vedanta Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of VE202 for the Treatment of Ulcerative Colitis and Receives Fast Track Designation
2023-09-28 07:38U:PRTCNews ReleaseKarXT, invented at PureTech, submitted for FDA Approval in Schizophrenia